Last reviewed · How we verify

Usual Care Inhaled Glucocorticosteroids

AstraZeneca · FDA-approved active Small molecule

Inhaled glucocorticosteroids reduce airway inflammation by binding to glucocorticoid receptors in lung tissue, suppressing inflammatory cytokine production and immune cell activation.

Inhaled glucocorticosteroids reduce airway inflammation by binding to glucocorticoid receptors in lung tissue, suppressing inflammatory cytokine production and immune cell activation. Used for Asthma maintenance therapy, Chronic obstructive pulmonary disease (COPD).

At a glance

Generic nameUsual Care Inhaled Glucocorticosteroids
SponsorAstraZeneca
Drug classInhaled corticosteroid (ICS)
TargetGlucocorticoid receptor (GR)
ModalitySmall molecule
Therapeutic areaRespiratory / Pulmonology
PhaseFDA-approved

Mechanism of action

Glucocorticosteroids are potent anti-inflammatory agents that work by translocating to the nucleus and modulating gene expression of inflammatory mediators. When inhaled directly into the lungs, they achieve high local concentrations while minimizing systemic exposure, reducing airway inflammation, mucus production, and bronchial hyperresponsiveness in asthma and COPD.

Approved indications

Common side effects

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape: